The interplay of diet and the microbiota may influence gut inflammation

The results of a recent study suggest that certain dietary changes can counteract bacterial functions that promote disease. The findings thus underscore the importance of examining microbial functions to understand…

Seed Health introduces revolutionary vaginal microbiome product: VS-01

The product, based on the pioneering research of Dr. Jacques Ravel, is the first of its kind to be clinically validated for establishing an optimal vaginal microbiome, dominated by Lactobacillus…

SynBalance Srl secures dual honors at 2024 NutraIngredients Awards

The company was honored with the Ingredient of the Year award in the Microbiome Modulation and the Beauty from Within category.

Microbial signature linked to improved response to immunotherapy in older people

The findings of a recent study highlight the importance of considering age-related immune changes and gut microbiota composition for developing personalized immunotherapy approaches.

Microbial metabolites promote colon cancer by suppressing anti-tumor responses

A recent study demonstrated causation between microbial DCA metabolism and anti-tumor CD8+ T cell response in colorectal cancer.

Biompharma’s Bi104 Receives FDA Orphan Drug Designation for Angelman Syndrome Treatment

Bi104 is a microbiome-modifying biologic designed to diversify and modulate the gut microflora and metabolite profile.

Miquel Bonachera discusses AB-BIOTICS’ new role on the IPA Board of Directors

AB-Biotics recently appointed to the IPA board of directors. What opportunities and future developments? We discussed this with Miquel Bonachera.

Cholesterol-metabolizing gut microbes may protect against heart disease

The findings of a recent study shed light on how the microbiota impacts cholesterol levels. They may also inform microbial-based interventions against high cholesterol.

Explore the future of wellness with SynBalance at Vitafoods

Join SynBalance at Vitafoods Europe 2024, held at Palexpo, Switzerland from May 14th to May 16th.

How some gut microbes improve responses to cancer immunotherapy

The findings of a recent study suggest that L. johnsonii or its metabolite IPA could be used as a microbial-based approach to improve a person’s response to immunotherapy.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top